Pfizer Inc :Pfizer Announces Positive Top-Line Results From Phase 2B/3 Trial Of Ritlecitinib In Alopecia Areata.Pfizer Inc - Allegro 2B/3 Trial Met Primary Efficacy Endpoint Of Improving Scalp Hair Regrowth.Pfizer Inc - Safety Profile Seen With Ritlecitinib Was Consistent With Previous Studies.Pfizer Inc - Percentage Of Patients With Adverse Events (Aes), Serious Aes And Discontinuing Due To Aes Was Similar Across All Treatment Groups.Pfizer Inc - Full Results From Study Will Be Submitted For Future Scientific Publication And Presentation.Pfizer Inc - Data From Study, Together With Data That Will Become Available From Allegro-Lt, Will Form Basis For Planned Future Regulatory Filings..
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments